Angela DeMichele
Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.
Medical oncologist who conducted the first-in-breast-cancer palbociclib study, co-leads I-SPY 2, and studies disseminated tumour cell dormancy as a target for preventing late recurrence.
| Title | Journal | Year |
|---|---|---|
| CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment | Clinical Cancer Research | 2015 |
Pages like this
not linked directly; found by shared links- TrialPALOMA-2
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- TrialPALLAS & PENELOPE-B
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- TrialINAVO120
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- InstitutionInstituto Alexander Fleming
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- CompanyCircle Pharma
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonDebu Tripathy
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonMitchell D. Schnall
Shares Abramson Cancer Center, University of Pennsylvania, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- TrialpersevERA
Shares Palbociclib, HR-positive / HER2-negative breast cancer.